Norvasc REDUCES cardiovascular morbidity and mortality in patients with coronary artery disease

New evidence suggests that Norvasc REDUCES cardiovascular morbidity and mortality in patients with coronary artery disease.

This new info comes from the PREVENT trial...designed to see whether Norvasc can slow the progression of atherosclerosis.

It suggests that patients on Norvasc have a 31% lower risk of MI...stroke...and hospitalizations or death from heart disease.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote